Pre-clinical proof-of-concept studies exploring schedules of administration of an adenovirus-based HBV immunotherapeutic show wide potential for induction of robust and long-lasting T-cell responses.


Houda Boukhebza, et al.
Journal of Hepatology, 2013, (58), Supplement 1, S161 – Download the article
Publication